Hogan Lovells 2024 Election Impact and Congressional Outlook Report
Hogan Lovells advises EyePoint Pharmaceuticals on its US$161 million follow-on public offering of common stock
Press releases
| 08
November
2024
Philadelphia, 8 November, 2024 – Global law firm Hogan Lovells advised EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) on its US$161 million follow-on public offering of 14,636,363 shares of common stock at a public offering price of US$11.00 per share.
EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases.
This comes on the heels of our previous work with EyePoint Pharmaceuticals. In December 2023, we advised the company on its US$230 million follow-on public offering of common stock. More details on that transaction can be found here.
The Hogan Lovells Philadelphia-based team was led by partner Stephen Nicolai, senior associate Gibby Wagner, and associate Kayvon Paul.
Press contacts
Press contacts
